BSX
🔒 LOCKEDBoston Scientific Corporation
🔒 Unlock Full Analysis
Sign in and use 1 credit to see AI verdict, intrinsic value, SWOT analysis, and all premium insights.
AI Executive Summary
Boston Scientific is a leading medical device company poised for continued growth due to an aging population and innovative product offerings, but its current valuation appears stretched.
The Business DNA
Boston Scientific develops and manufactures a wide range of medical devices across various interventional specialties, including cardiovascular and MedSurg. The company benefits from a diversified product portfolio and a strong competitive position in key markets. Their focus on innovation and addressing unmet medical needs allows them to maintain a technological edge. The aging global population further supports demand for their products.
Financial Health
Valuation Analysis
The current price-to-earnings ratio of 48.77 and forward P/E of 26.26 suggest that the stock is trading at a premium. The price-to-sales ratio of 6.99 is also relatively high. While the target mean price is $124.03, a more conservative valuation based on earnings and growth potential suggests an intrinsic value closer to $95, indicating the stock may be slightly overvalued at its current price.
Risks & Catalysts
Final Verdict: 🔒 LOCKED
Want More AI-Powered Analysis?
Get unlimited stock analyses, portfolio tracking, and real-time alerts
Related Stock Analyses
This analysis is generated by AI and should not be considered financial advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Last updated: 3/16/2026